One might surmise that by the time FDA asks an advisory committee to vet an application, the questions would deal primarily with clinical utility.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
